February 18, 2021 GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests February 16, 2021 GBS Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update December 28, 2020 GBS, Inc. Announces Closing of Upsized $21.6 Million Initial Public Offering December 23, 2020 UPDATE - GBS Inc. Announces Pricing of $21.6 Million Initial Public Offering December 22, 2020 GBS Inc. Announces Pricing of Initial Public Offering May 29, 2020 The iQ Group Global Partners with Harvard University for Real-Time, Printable COVID-19 Diagnostic Test May 6, 2020 FDA Engagement Commences for Saliva Glucose Biosensor in the US February 26, 2019 The iQ Group Global Introduces the Saliva Glucose Biosensor
February 18, 2021 GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests
February 16, 2021 GBS Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
May 29, 2020 The iQ Group Global Partners with Harvard University for Real-Time, Printable COVID-19 Diagnostic Test